Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05774613
Other study ID # Hibiscus Sabdariffa
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 12, 2021
Est. completion date June 30, 2023

Study information

Verified date March 2023
Source Instituto Tecnológico y de Estudios Superiores de Occidente
Contact Edgar J. Mendivil, Doctor
Phone 011523335784872
Email mendivil@iteso.mx
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There are numerous plant foods that are a source of bioactive compounds, which can induce an anti-inflammatory effect on various pathways of inflammatory processes in the body as it may be useful in decreasing markers of inflammation expressed by COVID-19 infectious disease and conditions such as obesity and its comorbidities. Given the above, Hibiscus sabdariffa hibiscus possesses advantages as a potential adjuvant in the management of COVID-19, as studies on the phytochemical properties of H. sabdariffa show that it has several health benefits, and could be used as a potent material for the therapeutic treatment of various diseases. Due to its high content of bioactive compounds, these can exert antioxidant, anti-inflammatory and anticarcinogenic effects, as well as help control blood glucose levels, prevent cardiovascular disease and obesity. In addition, it is a traditional component of the Mexican diet, of common consumption, easy incorporation in the diet, versatility in preparation and national production. Therefore, to evaluate the bioavailability of bioactive compounds present in a beverage developed from the TECNM/ITESO collaboration, as well as the glycemic and insulinemic response produced by its consumption; besides establishing the effect on some inflammation markers that may be activated as a consequence of the SARS-COV-2 virus infection. This will help to increase knowledge about potential treatment/prevention schemes, avoid the development of severe manifestations of the disease, as well as boost the production and market of a national product.


Description:

The following study will be carried out in two stages where an acute single-blind, crossover, randomized, single-blind clinical study will be performed, where 12 volunteers between 18 and 40 years of age, normal weight (BMI 18.5-24.9 kg/m2), without existing pathologies and/or with pharmacological treatment will be required. The characteristics of the study will be explained to the volunteers beforehand, and those who agree with the specifications will sign the informed consent form and become candidates to participate. The study will consist of the administration of a treatment drink based on hibiscus (H. sabdariffa), controlled with a placebo drink, both with a volume of 60 ml. The first stage will consist of the selection of volunteers who will undergo two interventions. On the day of the 1st intervention, participants will arrive at 7 a.m., central time in Mexico, with an overnight fast of 10-12heures . Prior to the intervention, the clinical history including anthropometric measurements and dietary questionnaire (24eures reminder) will be filled out and participants will be asked to rest for 30 min prior to taking their blood pressure at the time of admission, and they should be seated, upright and with their feet on the floor during the process; the measurement will be performed using a manometer on the left arm, elevated at the level of the heart. Afterwards, samples (urine and blood) were taken. Those corresponding to urine will be taken a basal sample (T=0) in a collection bottle. Once the hibiscus-based drink or placebo is ingested, samples will be collected at the following times: 3h, 6h, 12h and 24h. The samples corresponding to blood will be collected with the help of collecting tubes by venous puncture. Eight samples were taken, the first one at the arrival of the patients being basal time (T=B), then at 30 minutes (T=2), 1heure (T=3), 1:30heures (T=4), 2heures (T=5), 3heures (T=6), 4heures (T=7) and 6heures (T=8) after having ingested the hibiscus-based drink or the placebo. During the intervention the volunteers will receive a Western-type diet after the consumption of the beverage, characterized by excessive consumption of red meat, simple carbohydrates, ultra-processed products, colorants, saturated fats, refined sugars and very little intake of fiber and vitamins. After a washout period of more than 6 days, the participants will undergo a second intervention with a different product than the first time (beverage to be evaluated or placebo as appropriate), and the sampling will be repeated. The second stage will correspond to the evaluation of the glycemic response (GR) and insulinemic response (IR) of the selected individuals. For this purpose, volunteers should come with homogenized dietary conditions (normocaloric and carbohydrate-controlled diet (300 g/day)), without having performed intense physical activity and with a fasting state of 12 hours; In the place they will consume the treatment drink (BT) and the placebo drink (BP) of 60 mL, accompanied by a portion of white bread, so that the sum of the drink plus the white bread will be 50 g of carbohydrates, the administration of the type of drink will be carried out in different sessions, separated by a washout period of 7 days, so that the participants will consume a different one in each session. The RG and RI will be evaluated at time 0 (preprandial), and at 15, 30, 45, 60, 90, and 120 minutes (postprandial), through capillary blood obtained by fingertip puncture. The evaluation corresponding to the GR will be done by taking the second drop and placing it on highly sensitive test strips of the OneTouch Ultra® System, continuing with the determination of the RI through the collection of blood in BD Microtainer SST tubes, which will be centrifuged for 10 minutes (5000 rpm, 25°C) to obtain the serum, which will be used when employing an ELISA human insulin kit. The study will be carried out at the Nutricia clinic located in Building M of the Instituto Tecnológico y de Estudios Superiores de Occidente (ITESO) located at Anillo Perif. Sur Manuel Gómez Morín 8585, Santa María Tequepexpan, 45604 Tlaquepaque, Jalisco.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date June 30, 2023
Est. primary completion date June 13, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Normolipidemia Total cholesterol (plasma) < 200 mg/L-1 - Triglycerides < 150 mg/L-1 - Normoglycemia Fasting glucose (plasma) < 100 mg/L-1 - IMC [kg/m2]1 18.5 - 24.9 - Abdominal circumference [cm] Men<90 Women < 80 - Percentage of fat [%] Men<19 Women < 33Systolic pressure [mmHg] < 140 - Diastolic pressure [mmHg] < 90 - Alcohol Last consumption one and a half weeks Exclusion Criteria: - Hypertension - Diabetes - Smokers - Cardiovascular disease - Secondary hyperlipidemia - Renal insufficiency - Hyperthyroidism - In diet - Pregnant or lactating women, and if their menstrual cycle is close (1 week) - In medical treatment / supplements - Hepatic insufficiency - Infection / inflammatory disease (6 weeks prior to study)

Study Design


Intervention

Dietary Supplement:
Effect of a Hibiscus sabdariffa beverage
Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion

Locations

Country Name City State
Mexico ITESO Tlaquepaque Jalisco

Sponsors (2)

Lead Sponsor Collaborator
Instituto Tecnológico y de Estudios Superiores de Occidente Instituto Tecnológico de Tepic

Country where clinical trial is conducted

Mexico, 

References & Publications (9)

Achour M, Bravo L, Sarria B, Ben Fredj M, Nouira M, Mtiraoui A, Saguem S, Mateos R. Bioavailability and nutrikinetics of rosemary tea phenolic compounds in humans. Food Res Int. 2021 Jan;139:109815. doi: 10.1016/j.foodres.2020.109815. Epub 2020 Oct 20. — View Citation

Fernandez-Ochoa A, Cadiz-Gurrea ML, Fernandez-Moreno P, Rojas-Garcia A, Arraez-Roman D, Segura-Carretero A. Recent Analytical Approaches for the Study of Bioavailability and Metabolism of Bioactive Phenolic Compounds. Molecules. 2022 Jan 25;27(3):777. doi: 10.3390/molecules27030777. — View Citation

Hossain MM, Tovar J, Cloetens L, Florido MTS, Petersson K, Prothon F, Nilsson A. Oat Polar Lipids Improve Cardiometabolic-Related Markers after Breakfast and a Subsequent Standardized Lunch: A Randomized Crossover Study in Healthy Young Adults. Nutrients. 2021 Mar 18;13(3):988. doi: 10.3390/nu13030988. — View Citation

Janson B, Prasomthong J, Malakul W, Boonsong T, Tunsophon S. Hibiscus sabdariffa L. calyx extract prevents the adipogenesis of 3T3-L1 adipocytes, and obesity-related insulin resistance in high-fat diet-induced obese rats. Biomed Pharmacother. 2021 Jun;138:111438. doi: 10.1016/j.biopha.2021.111438. Epub 2021 Mar 13. — View Citation

Li S, Wu B, Fu W, Reddivari L. The Anti-inflammatory Effects of Dietary Anthocyanins against Ulcerative Colitis. Int J Mol Sci. 2019 May 27;20(10):2588. doi: 10.3390/ijms20102588. — View Citation

Marhuenda J, Perez S, Victoria-Montesinos D, Abellan MS, Caturla N, Jones J, Lopez-Roman J. A Randomized, Double-Blind, Placebo Controlled Trial to Determine the Effectiveness a Polyphenolic Extract (Hibiscus sabdariffa and Lippia citriodora) in the Reduction of Body Fat Mass in Healthy Subjects. Foods. 2020 Jan 6;9(1):55. doi: 10.3390/foods9010055. Erratum In: Foods. 2020 Mar 03;9(3): — View Citation

Sayago-Ayerdi SG, Goni I. [Hibiscus sabdariffa L: source of antioxidant dietary fiber]. Arch Latinoam Nutr. 2010 Mar;60(1):79-84. Spanish. — View Citation

Sayago-Ayerdi SG, Venema K, Tabernero M, Sarria B, Bravo L, Mateos R. Bioconversion of polyphenols and organic acids by gut microbiota of predigested Hibiscus sabdariffa L. calyces and Agave (A. tequilana Weber) fructans assessed in a dynamic in vitro model (TIM-2) of the human colon. Food Res Int. 2021 May;143:110301. doi: 10.1016/j.foodres.2021.110301. Epub 2021 Mar 10. — View Citation

Wolever TM, Jenkins DJ. The use of the glycemic index in predicting the blood glucose response to mixed meals. Am J Clin Nutr. 1986 Jan;43(1):167-72. doi: 10.1093/ajcn/43.1.167. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Bioavalability of fenolics compunds and organic acids identification and quantification of bioactive compounds in plasma and urine samples by HPLC-DAD-MS liquid chromatography. the time period will be determined in a single day by evaluating absorption at 0, 0.5, 1, 2, 3, 4, 5 and 6 hours in plasma and for urine its excretion evaluated at 0, 3, 6, 12, 24 hours.
Primary Glycemic response 0 minutes (preprandial) and de next repsponse at 15, 30, 45, 60, 90 and 120 minutes To obtain the biological sample, a lancet will be used to puncture the pad of the voluntary finger and the sample will be collected in high-sensitivity reactive strips for the measurement of capillary glucose of the OneTouch Ultra System. The portable systeme used for pre- and postprandial glucose measurement allows the monitoring of the capillary glycemic response under experimental conditions for healthy subjects. With the use of this equipment, preprandial and postprandial measurements will be obtained. With the use of this equiment, measurements will be obtained from 0 minutes (preprandial) and at 15, 30, 45, 60, 90 and 120 minutes (postprandial) response
Primary Insulinemic response 0 minutes (pre-prandial) Blood samples will be drawn via capillary puncture. Measurements over time will be similar to the glycemic response assessment techniqeu. Samples will be placed in BD Microtainer SST tubes and kept at room temperature for 30 min. The samples will be centrifucated to obtain serum. Serum insulin concentrations will be analyzed using a solid-phase two-site enzyme immunoassay kit (Human Insulin ElLISA kit, Millipore, EZHI-14K) The obtaining of the samples will be taken at 0 minutes (pre-prandial)
Primary Insulinemic response15 minutes Blood samples will be drawn via capillary puncture. Measurements over time will be similar to the glycemic response assessment techniqeu. Samples will be placed in BD Microtainer SST tubes and kept at room temperature for 30 min. The samples will be centrifucated to obtain serum. Serum insulin concentrations will be analyzed using a solid-phase two-site enzyme immunoassay kit (Human Insulin ElLISA kit, Millipore, EZHI-14K) The obtaining of the samples will be taken at 15 minutes
Primary Insulinemic response 30 minutes Blood samples will be drawn via capillary puncture. Measurements over time will be similar to the glycemic response assessment techniqeu. Samples will be placed in BD Microtainer SST tubes and kept at room temperature for 30 min. The samples will be centrifucated to obtain serum. Serum insulin concentrations will be analyzed using a solid-phase two-site enzyme immunoassay kit (Human Insulin ElLISA kit, Millipore, EZHI-14K) The obtaining of the samples will be taken at 30 minutes
Primary Insulinemic response 45minutes Blood samples will be drawn via capillary puncture. Measurements over time will be similar to the glycemic response assessment techniqeu. Samples will be placed in BD Microtainer SST tubes and kept at room temperature for 30 min. The samples will be centrifucated to obtain serum. Serum insulin concentrations will be analyzed using a solid-phase two-site enzyme immunoassay kit (Human Insulin ElLISA kit, Millipore, EZHI-14K) The obtaining of the samples will be taken at 45minutes
Primary markers of inflammation IL-6 To perform an assay of inflammation markers by proquantum kit specifically interleukin-6 to visualize the decrease of these markers. The blood samples will take with the help of collecting tubes by venous puncture, with 8 samples, t=0, then at 30 minutes, 1, 2, 3, 4 5 and 6 hours and Urine samples will be collected at 0, 3,6, 12, 24 hours
Secondary Anthropometry measurements measurements will be taken with the Inbody 770 equipment, whose results include weight, height, fat percentages and body muscle mass on the same day to evaluate the volunteers' measurements on the day of the intervention. only measure
Secondary Food intake Using Food Frecuency Quertionnaire and 24 hours reminder 2 weeks for the response
See also
  Status Clinical Trial Phase
Completed NCT00074451 - Genomewide Search for Loci Underlying Metabolic Syndrome
Completed NCT00073775 - Epidemiology of Stress and the Metabolic Syndrome N/A
Completed NCT00005709 - Lipoprotein Metabolism in Hypertensive African-Americans N/A
Completed NCT00005380 - Insulin, Androgen, and Risk in African-American Women N/A
Recruiting NCT05088798 - Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism Phase 2
Not yet recruiting NCT05950282 - Fasting Insulin and HOMA-IR by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis
Completed NCT02248272 - Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes N/A
Completed NCT00937079 - Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients Phase 1
Completed NCT00151684 - Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men Phase 2
Completed NCT00004825 - Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism N/A
Completed NCT00005530 - Diet, Insulin Resistance, and Cardiovascular Risk N/A
Recruiting NCT05662189 - Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus N/A
Recruiting NCT04744896 - Effects Of Combined Cryolipolysis And High Intensity Interval Training On Insulin Resistance And Body Composition In Polycystic Ovarian Patients N/A
Completed NCT05329337 - Link Between the Peripheral Mononuclear Cells' Capacity to Induce Insulin Resistance and Hyperinsulinemia N/A
Not yet recruiting NCT05989347 - Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy Phase 1
Recruiting NCT05543083 - Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes N/A
Recruiting NCT06363929 - Continuous Glucose Monitoring in Neonatal Hyperinsulinism
Completed NCT03358745 - Impact of Meal Order on Postprandial Cardiometabolic Risk Markers N/A
Not yet recruiting NCT05764200 - Acute Microbial Switch N/A
Completed NCT00005104 - Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome N/A